Acute StrokePhase 3ESTRELNCT03735901
Enhancement of Stroke Rehabilitation With Levodopa
A Phase 3 study testing IMP Levodopa 100mg/Carbidopa 25mg in people with Acute Stroke and Stroke Rehabilitation, run by University Hospital, Basel, Switzerland at 24 sites in Switzerland.
Trial summary
Trial investigates the benefits and harms of Levodopa /Carbidopa 100/25mg compared to placebo (given in addition to standardized rehabilitation based on the principles of motor learning) and whether there is an association with a patient-relevant enhancement of functional recovery in acute stroke patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Stroke, Stroke Rehabilitation
- What is being tested?
- IMP Levodopa 100mg/Carbidopa 25mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 610 participants
- Where
- 24 sitesSwitzerland
- Study dates
- 14 Jun 2019to 30 Jun 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Acute ischemic or hemorrhagic (i.e. intracerebral hemorrhage excluding subarachnoid hemorrhage and cerebral venous sinus thrombosis) stroke ≤ 7 days prior to randomization
- Clinically meaningful hemiparesis (i.e. scoring a total of ≥ 3 points on the following NIH stroke scale score items (i) motor arm, (ii) motor leg, (iii) limb ataxia; a distal arm paresis is equivalent to one of the aforementioned (i-iii))
- Time of randomization ≥24-hours since thrombolysis or thrombectomy
- In-hospital rehabilitation required
- Capable to participate in standardized rehabilitation therapy
- Informed consent of patient or next of kin
Who cannot join
- Diagnosis of Parkinson's Disease
- Use of Levodopa mandatory according to judgement of treating physician
- Inability or unwillingness to comply with study procedures including adherence to study drug intake (orally, or via nasogastric tube or percutaneous endoscopic gastrostomy tube)
- Severe aphasia (i.e. unable to follow two-stage-commands)
- Previously dependent in the basal activities of daily living (defined as modified Ranking Scale prior to stroke > 3)
- Pre-existing hemiparesis
Show all 9Show fewer
- Known hypersensitivity to Levodopa/Carbidopa and other contraindications for Levodopa/Carbidopa as outlined in the summary of product characteristics
- Women who are pregnant or breast feeding, or who intend to become pregnant during the course of the study. Women of childbearing age must take a pregnancy test to be eligible for the study.
- Lack of safe contraception, defined as: Female Participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the Investigator in individual cases. Female Participants who are surgically sterilized / hysterectomized or post- menopausal for longer than 2 years are not considered as being of child- bearing potential.
Trial locations and contacts
24 sites in 1 country.
24 sites in 1 country
Switzerland24 sites
Kantonsspital Aarau, Neurozentrum
Aarau, 5001
RehaClinic AG
Bad Zurzach, 5330
Kantonsspital Baden
Baden, 5404
Felix Platter Spital
Basel, 4002
Stroke-Center Universitätsspital Basel
Basel
Inselspital, Universitätsklinik für Neurologie
Bern, 3010
Kantonsspital Graubünden, Departement Innere Medizin / Neurologie
Chur, 7000
HFR Fribourg Hopital Cantonal, U. de Neurologie
Fribourg, 1708
Centre hospitalier universitaire vaudois, Service de Neurologie
Lausanne, 1011
HFR Meyriez-Murten, Clinique de Réhabilitation
Meyriez, 3280
Kantonsspital Münsterlingen
Münsterlingen, 8596
Reha Rheinfelden
Rheinfelden, 4310
Kantonsspital St.Gallen, Klinik für Neurologie
Sankt Gallen, 9007
Hôpital du Valais - Sion, Service de neurologie
Sion, 1950
Hôpital du Valais - Sion
Sion, 1950
Rehazentrum Valens, Klinik für Neurologie und Neurorehabilitation
Valens, 7317
Cereneo Schweiz AG
Vitznau, 6354
Zürcher RehaZentrum Wald
Wald, 8636
Rheinburg Klinik AG
Walzenhausen, 9428
Kantonsspital Winterthur
Winterthur, 8401
Rehaklinik Zihlschlacht
Zihlschlacht, 8588
Klinik Lengg AG
Zurich, 8008
Head Stroke Center Klinik Hirslanden
Zurich, 8032
Universitätsspital Zürich, Klinik für Neurologie
Zurich, 8091
About this study
Official title: Enhancement of Stroke Rehabilitation With Levodopa (ESTREL): a Randomized Placebo-controlled Trial
Trial investigates the benefits and harms of Levodopa /Carbidopa 100/25mg compared to placebo (given in addition to standardized rehabilitation based on the principles of motor learning) and whether there is an association with a patient-relevant enhancement of functional recovery in acute stroke patients. Study participants will be randomized 1:1.
Read the detailed description
Trial investigates whether Levodopa/Carbidopa compared to placebo given in addition to standardized rehabilitative therapy in patients with acute stroke is associated with
- patient relevant improvements of physical function b) improvement in patient-self assessed general health aspects, pain, mood, anxiety, fatigue and social participation c) long-term sustainability of a patient-relevant improvement of motor function d) improvement of selective hand and wrist movement e) a higher rate of patients walking independently of the help of another person.
- less severe impairment g) a higher level of activity of daily living h) improvements of quality of life (i) better cognitive performance (j) no signals of harms (i.e. indications for increased all-cause mortality, recurrent stroke, serious adverse events, and non-serious, pre-specified adverse events possibly related to the IMP)
Estrel-Longterm: optional prolongation of the observational study phase. To investigate the long-term outcomes of our study population the investigator aim to offer an optional prolongation of the observational phase to the participants through regular structured (once yearly) telephone visits.
The telephone visits will be carried out annually for the following 4 years.
- Conditions
- Acute Stroke, Stroke Rehabilitation
- Being tested
- IMP Levodopa 100mg/Carbidopa 25mg, Matching placebo
- Keywords
- Levodopa / Carbidopa, Fugl-Meyer-Motor-Assessment (FMMA), Acute ischemic stroke, Acute hemorrhagic stroke, Rehabilitation, Recovery, Randomized controlled trial
- Medical subject headings
- Stroke, Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IMP Levodopa 100mg/Carbidopa 25mgDrug
Study treatment will comprise 3 phases:
- Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;
- full study treatment phase: from day 7 to day 34, 3 times per day (tid).
- Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning.
Matching placeboDrug
Study treatment will comprise 3 phases:
- Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;
- full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).
- Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning.
| Study group | Role | What they receive |
|---|---|---|
| Experimental Intervention | Active comparator | White Investigational Medicinal Product (IMP)- capsules of a combination of IMP Levodopa 100mg/Carbidopa 25mg. Receives: Drug: IMP Levodopa 100mg/Carbidopa 25mg |
| Control Intervention | Placebo comparator | Matching placebo, identical in aspect, texture, and taste when compared to the IMP. Procedures regarding route of administration, study treatment duration and treatment phases will be identical in the IMP- and the placebo-group. Receives: Drug: Matching placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fugl-Meyer-Motor Assessment Score (FMMA)
FMMA is a stroke-specific impairment index designed to assess motor recovery. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale (0=cannot perform; 1=performs partially and 2= performs fully). FMMA total scores range from 0 (no movements) to 100 (normal movements) with 66 points for movements of the upper limbs (FMMA-UE) and 34 for those of the lower limbs (FMMA-LE). A difference of 5.25 points for the upper extremity and 6 points for the lower extremity part of the score are described as minimal clinically important difference. For this study, based on these data, 6 points difference are considered a patient-relevant difference between both treatment groups for the primary endpoint.
Measured: Assessed 3 months +/- 14 days after randomization
Secondary outcomes (20)
NIH-Stroke Scale Score (NIHSS)
To objectively quantify the impairment caused by a stroke. NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For this study, an extra item for distal arm paresis was included (score from 0-2). For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (+4 for distal arm paresis), with the minimum score being a 0.
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Modified Rankin Scale Score (mRS)
Scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.
0 - No symptoms.
- - No significant disability. Able to carry out all usual activities, despite some symptoms.
- - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- - Moderate disability. Requires some help, but able to walk unassisted.
- - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- - Dead.
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Stroke rehabilitation outcomes for disease specific morbidity and quality of life - PROMIS 29
Patient-self-assessment in the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity. Each of the domains 1 to 7 are assessed with 4 questions. Items are scored on 1 of 5 levels based on the ability of the participant to perform activities or the self-assessment of the participant in the various domains. Pain intensity is scored on a visual analogue scale of 0 to 10.
Measured: Assessed 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Stroke rehabilitation outcomes for disease specific morbidity and quality of life - PROMIS 10
Patient-self-assessment Patient-Reported Outcomes Measurement Information System (PROMIS) 10 addresses general health aspects, quality of life, pain, mood, anxiety, fatigue and social participation; PROMIS-10 covers the outcome domains considered most important
Measured: Assessed 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Patient-reported assessment of relevance of motor improvement
Patients Questionnaire asking whether there is improvement in motor function since the last study visit and if so, whether this improvement is relevant in patients' personal perception (yes/ no).
Measured: Assessed 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Rivermead Mobility Index (RMI)
15 items that measure the ability of patients to make postural adjustments (e.g, move in bed), transfer (e.g. between bed to chair), walk, and use stairs and is scored from 0-15 Points. A RMI score of ≥ 7 translates into the ability of the patient walking independently of the assistance of another Person.
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Mortality (of any cause)
death rate
Measured: Throughout the whole study period from Day 1 to Visit 12/24/36/48/60 months +/- 30 days after randomization
Recurrent stroke (any type)
recurrent stroke (any type)
Measured: Throughout the whole study period from Day 1 to Visit 12/24/36/48/60 months +/- 30 days after randomization
Pre- specified Adverse Events of Interest
Nausea, Vomiting, Taste disturbances, Dry mouth, Anorexia, Arrhythmias, Postural hypotension Syncope (unconsciousness for a short time as a result of reduced blood flow to the brain), drowsiness (including sudden onset of sleep) Fatigue, Dementia, Psychoses (a distorted perception of reality), Hallucinations, Confusion, Euphoria, Abnormal dreams, Insomnia, Depression, Anxiety, Dizziness, Dystonia (involuntary contractions), Dyskinesia (inability to control voluntary movements), Chorea (sudden twitching of the face and shoulders)
Measured: Throughout the study period from Day 1 to Visit 3 ( 3 months +/- 14 days after randomization)
Motricity Index (MI)
Two subscales, one for the upper extremity (UE) (total score range 0 to 100) and one for the lower extremity (LE) (total score range 0 to 100). It measures isometric muscle strength (0 = no movement; 100 = normal)
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Trunk Control Test (TCT)
Assesses the trunk abilities of the patient , contains 4 items, with item scores ranging from 0 to 25. The sitting balance item assesses the patients' ability to sit during 30 seconds without trunk and feet support and has a predictive value for recovery of walking poststroke
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Action Research Arm Test (ARAT)
Assesses the patients' ability to grasp (subscale with 6 items), grip (subscale with 4 items), pinch (subscale with 6 items) and perform gross movements (subscale with 3 items) with the upper extremity. Score: 0 = no movement / 1= movement task is partially performed / 2 = movement task is completed but takes abnormally long / 3 = movement is performed normally
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Box- and Block Test (BBT)
Patients (seated in front of a square box with two compartments) are asked to move as many wooden cubes as possible from one compartment to the other within 60 seconds of testing time.
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Functional Ambulation Categories (FAC)
Classification (score range 0 to 5) regarding the ability to walk independently, with or without a walking aid and takes the type of walking surface into account.
Rating:
0 = Patient cannot walk, or needs help from 2 or more persons
- = Patient needs firm continuous support from 1 person who helps carrying weight and with balance
- = Patient needs continuous or intermittent support of one person to help with balance and coordination
- = Patient requires verbal supervision or stand-by help from one person without physical contact
- = Patient can walk independently on level ground, but requires help on stairs, slopes or uneven surfaces
- = Patient can walk independently anywhere
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Ten-Meter Walk Test (10MWT)
Walking speed and cadence over a 10 meter track at both a comfortable and a maximum Speed; time in seconds over 10-meter walking distance
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Jamar dynamometer testing (JDT)
grip strength and strength of the forearm (in kilogram)
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Montreal Cognitive Assessment (MoCA)
Assesses cognitive domains: Short-term memory recall task (5 points).Visuospatial abilities assessed using clock-drawing task (3 points) and 3-dimensional cube copy (1 point). Executive functions assessed using alternation task. Attention, concentration, working memory evaluated using a sustained attention task (target detection using tapping; 1 point), serial subtraction task (3 points), digits forward and backward (1 point each). Languages assessed using 3-item confrontation naming task with low-familiarity animals (lion, camel, rhinoceros; 3 points), repetition of 2 complex sentences (2 points), and fluency task. Orientation to time and place evaluated by asking for date and city in which the test is occurring (6 points). A score of 26 or over is considered to be normal (range 0 to 30)
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Daily activity measurement with movement sensor
Movement sensors allow assessment of physical activity engagement and upper limb use in daily life situations without physically hampering the patient in the performance of their daily activities
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Serious Adverse Event (SAE)
Any untoward medical occurrence that:
- results in death,
- is life-threatening,
- requires in-patient hospitalization or prolongation of existing hospitalisation,
- results in persistent or significant disability/incapacity, or
- is a congenital anomaly/birth defect
Measured: Throughout the study period from Day 1 to Visit 3 ( 3 months +/- 14 days after randomization)
Fugl-Meyer-Motor Assessment Score (FMMA)
FMMA is a stroke-specific impairment index designed to assess motor recovery. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale (0=cannot perform; 1=performs partially and 2= performs fully). FMMA total scores range from 0 (no movements) to 100 (normal movements) with 66 points for movements of the upper limbs (FMMA-UE) and 34 for those of the lower limbs (FMMA-LE). A difference of 5.25 points for the upper extremity and 6 points for the lower extremity part of the score are described as minimal clinically important difference. For this study, based on these data, 6 points difference are considered a patient-relevant difference between both treatment groups for the primary endpoint.
Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2018
- Study start14 Jun 2019
- Primary completion27 Aug 2024
- Study completion30 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Acute StrokeStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Study participants will be randomized 1:1
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 610 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Collaborators
- Swiss National Science Foundation
- Responsible party
- Sponsor
- Investigators
- Stefan Engelter, Prof. MD, Principal investigator, Felix-Platter Spital Basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03735901
- Sponsor's protocol ID
- 2018-02021; me16Engelter
- Other IDs
- 2018
- Acronym
- ESTREL
- Status last verified
- Oct 2024
- First submitted
- 7 Nov 2018
- Last updated
- 15 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Trussel S, Traenka CK, Polymeris A, Enz L, Zietz A, Altersberger VL, Wiesner K, Katan M, Lyrer PA, Goga I, Engelter S, Luft AR, Rottenberger Y, Schwarz A, Medlin F, Muri RM, Seiffge D, Fischer U, Michel P, Peters N, Kagi G, Politz S, Tarnutzer A, Nedeltchev K, Bonati L, Schuster-Amft C, Moller JC, Bujan B, Sandor PS, Gonzenbach R, Mylius V, Lienert C, Held J, Schaedelin S, Hemkens LG, Ford GA, Kaufmann JE, Gensicke H, Engelter ST. Time course of motor recovery after stroke with and without levodopa: a post hoc 6-month longitudinal analysis of the ESTREL trial. Eur Stroke J. 2026 Jul 6;11(7):aakag089. doi: 10.1093/esj/aakag089.
PubMed 42525438Sauter MI, Kaufmann JE, Boos L, Zietz A, Trussel S, Luft AR, Polymeris A, Altersberger VL, Wiesner K, Wiegert M, Held JPO, Rottenberger Y, Schwarz A, Medlin F, Accolla EA, Foucras S, Kagi G, De Marchis GM, Politz S, Greulich M, Tarnutzer AA, Sturzenegger R, Katan M, Arnold M, Nedeltchev K, Schar J, Deglon KVDK, Rapin PA, Salerno A, Seiffge DJ, Auer E, Lippert J, Bonati LH, Schuster-Amft C, Gaumann S, Chabwine JN, Humm A, Moller JC, Schweinfurther R, Bujan B, Jedrysiak P, Sandor PS, Gonzenbach R, Mylius V, Lutz D, Lienert C, Peters N, Michel P, Muri RM, Schadelin S, Hemkens LG, Ford GA, Lyrer PA, Gensicke H, Traenka C, Engelter ST. The impact of levodopa on post-stroke depression: the ESTREL-depression-study. Eur Stroke J. 2026 Feb 9;11(2):aakag001. doi: 10.1093/esj/aakag001.
PubMed 41701756Engelter ST, Kaufmann JE, Zietz A, Luft AR, Polymeris A, Altersberger VL, Wiesner K, Wiegert M, Held JPO, Rottenberger Y, Schwarz A, Medlin F, Accolla EA, Foucras S, Kagi G, De Marchis GM, Politz S, Greulich M, Tarnutzer AA, Sturzenegger R, Katan M, Fischer U, Nedeltchev K, Schar J, Van Den Keybus Deglon K, Rapin PA, Salerno A, Seiffge DJ, Auer E, Lippert J, Bonati LH, Schuster-Amft C, Gaumann S, Chabwine JN, Humm A, Moller JC, Schweinfurther R, Bujan B, Jedrysiak P, Sandor PS, Gonzenbach R, Mylius V, Lutz D, Lienert C, Peters N, Michel P, Muri RM, Schadelin S, Hemkens LG, Ford GA, Lyrer PA, Gensicke H, Traenka C; ESTREL Investigators. Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial. JAMA. 2025 Nov 4;334(17):1523-1532. doi: 10.1001/jama.2025.15185.
PubMed 40982270
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Enhancement of Stroke Rehabilitation With Levodopa (ESTREL): a Randomized Placebo-controlled Trial
- ClinicalTrials.gov ID
- NCT03735901
- Acronym / sponsor ID
- ESTREL / 2018-02021; me16Engelter
- Conditions
- Acute Stroke, Stroke Rehabilitation
- Keywords
- Levodopa / Carbidopa, Fugl-Meyer-Motor-Assessment (FMMA), Acute ischemic stroke, Acute hemorrhagic stroke, Rehabilitation, Recovery, Randomized controlled trial
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 610 participants (actual)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Collaborators
- Swiss National Science Foundation
- Study start
- 14 Jun 2019 (actual)
- Primary completion
- 27 Aug 2024 (actual)
- Study completion
- 30 Jun 2029 (estimated)
- First posted
- 8 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Trial investigates the benefits and harms of Levodopa /Carbidopa 100/25mg compared to placebo (given in addition to standardized rehabilitation based on the principles of motor learning) and whether there is an association with a patient-relevant enhancement of functional recovery in acute stroke patients. Study participants will be randomized 1:1.
Detailed description
Trial investigates whether Levodopa/Carbidopa compared to placebo given in addition to standardized rehabilitative therapy in patients with acute stroke is associated with
- patient relevant improvements of physical function b) improvement in patient-self assessed general health aspects, pain, mood, anxiety, fatigue and social participation c) long-term sustainability of a patient-relevant improvement of motor function d) improvement of selective hand and wrist movement e) a higher rate of patients walking independently of the help of another person.
- less severe impairment g) a higher level of activity of daily living h) improvements of quality of life (i) better cognitive performance (j) no signals of harms (i.e. indications for increased all-cause mortality, recurrent stroke, serious adverse events, and non-serious, pre-specified adverse events possibly related to the IMP)
Estrel-Longterm: optional prolongation of the observational study phase. To investigate the long-term outcomes of our study population the investigator aim to offer an optional prolongation of the observational phase to the participants through regular structured (once yearly) telephone visits.
The telephone visits will be carried out annually for the following 4 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Study participants will be randomized 1:1
| Arm | Type | Receives |
|---|---|---|
| Experimental Intervention | Active comparator | Drug: IMP Levodopa 100mg/Carbidopa 25mgWhite Investigational Medicinal Product (IMP)- capsules of a combination of IMP Levodopa 100mg/Carbidopa 25mg. |
| Control Intervention | Placebo comparator | Drug: Matching placeboMatching placebo, identical in aspect, texture, and taste when compared to the IMP. Procedures regarding route of administration, study treatment duration and treatment phases will be identical in the IMP- and the placebo-group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Acute ischemic or hemorrhagic (i.e. intracerebral hemorrhage excluding subarachnoid hemorrhage and cerebral venous sinus thrombosis) stroke ≤ 7 days prior to randomization
- Clinically meaningful hemiparesis (i.e. scoring a total of ≥ 3 points on the following NIH stroke scale score items (i) motor arm, (ii) motor leg, (iii) limb ataxia; a distal arm paresis is equivalent to one of the aforementioned (i-iii))
- Time of randomization ≥24-hours since thrombolysis or thrombectomy
- In-hospital rehabilitation required
- Capable to participate in standardized rehabilitation therapy
Key exclusion criteria (9 listed)
- Diagnosis of Parkinson's Disease
- Use of Levodopa mandatory according to judgement of treating physician
- Inability or unwillingness to comply with study procedures including adherence to study drug intake (orally, or via nasogastric tube or percutaneous endoscopic gastrostomy tube)
- Severe aphasia (i.e. unable to follow two-stage-commands)
- Previously dependent in the basal activities of daily living (defined as modified Ranking Scale prior to stroke > 3)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IMP Levodopa 100mg/Carbidopa 25mgStudy treatment will comprise 3 phases: 1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time; 2. full study treatment phase: from day 7 to day 34, 3 times per day (tid). 3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning. | Drug | Experimental Intervention |
| Matching placeboStudy treatment will comprise 3 phases: 1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time; 2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid). 3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning. | Drug | Control Intervention |
Primary outcome
Fugl-Meyer-Motor Assessment Score (FMMA)
Time frame: Assessed 3 months +/- 14 days after randomization
FMMA is a stroke-specific impairment index designed to assess motor recovery. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale (0=cannot perform; 1=performs partially and 2= performs fully). FMMA total scores range from 0 (no movements) to 100 (normal movements) with 66 points for movements of the upper limbs (FMMA-UE) and 34 for those of the lower limbs (FMMA-LE). A difference of 5.25 points for the upper extremity and 6 points for the lower extremity part of the score are described as minimal clinically important difference. For this study, based on these data, 6 points difference are considered a patient-relevant difference between both treatment groups for the primary endpoint.
20 secondary outcomes
NIH-Stroke Scale Score (NIHSS)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Modified Rankin Scale Score (mRS)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Stroke rehabilitation outcomes for disease specific morbidity and quality of life - PROMIS 29
Time frame: Assessed 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Stroke rehabilitation outcomes for disease specific morbidity and quality of life - PROMIS 10
Time frame: Assessed 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Patient-reported assessment of relevance of motor improvement
Time frame: Assessed 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Rivermead Mobility Index (RMI)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Mortality (of any cause)
Time frame: Throughout the whole study period from Day 1 to Visit 12/24/36/48/60 months +/- 30 days after randomization
Recurrent stroke (any type)
Time frame: Throughout the whole study period from Day 1 to Visit 12/24/36/48/60 months +/- 30 days after randomization
Pre- specified Adverse Events of Interest
Time frame: Throughout the study period from Day 1 to Visit 3 ( 3 months +/- 14 days after randomization)
Motricity Index (MI)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Trunk Control Test (TCT)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Action Research Arm Test (ARAT)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Box- and Block Test (BBT)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Functional Ambulation Categories (FAC)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization
Ten-Meter Walk Test (10MWT)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Jamar dynamometer testing (JDT)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Montreal Cognitive Assessment (MoCA)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Daily activity measurement with movement sensor
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Serious Adverse Event (SAE)
Time frame: Throughout the study period from Day 1 to Visit 3 ( 3 months +/- 14 days after randomization)
Fugl-Meyer-Motor Assessment Score (FMMA)
Time frame: Assessed at Day 0 (Randomization), 5 weeks after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2024.
- Derived from this study: PubMed 42525438Trussel S, Traenka CK, Polymeris A, Enz L, Zietz A, Altersberger VL, Wiesner K, Katan M, Lyrer PA, Goga I, Engelter S, Luft AR, Rottenberger Y, Schwarz A, Medlin F, Muri RM, Seiffge D, Fischer U, Michel P, Peters N, Kagi G, Politz S, Tarnutzer A, Nedeltchev K, Bonati L, Schuster-Amft C, Moller JC, Bujan B, Sandor PS, Gonzenbach R, Mylius V, Lienert C, Held J, Schaedelin S, Hemkens LG, Ford GA, Kaufmann JE, Gensicke H, Engelter ST. Time course of motor recovery after stroke with and without levodopa: a post hoc 6-month longitudinal analysis of the ESTREL trial. Eur Stroke J. 2026 Jul 6;11(7):aakag089. doi: 10.1093/esj/aakag089.
- Derived from this study: PubMed 41701756Sauter MI, Kaufmann JE, Boos L, Zietz A, Trussel S, Luft AR, Polymeris A, Altersberger VL, Wiesner K, Wiegert M, Held JPO, Rottenberger Y, Schwarz A, Medlin F, Accolla EA, Foucras S, Kagi G, De Marchis GM, Politz S, Greulich M, Tarnutzer AA, Sturzenegger R, Katan M, Arnold M, Nedeltchev K, Schar J, Deglon KVDK, Rapin PA, Salerno A, Seiffge DJ, Auer E, Lippert J, Bonati LH, Schuster-Amft C, Gaumann S, Chabwine JN, Humm A, Moller JC, Schweinfurther R, Bujan B, Jedrysiak P, Sandor PS, Gonzenbach R, Mylius V, Lutz D, Lienert C, Peters N, Michel P, Muri RM, Schadelin S, Hemkens LG, Ford GA, Lyrer PA, Gensicke H, Traenka C, Engelter ST. The impact of levodopa on post-stroke depression: the ESTREL-depression-study. Eur Stroke J. 2026 Feb 9;11(2):aakag001. doi: 10.1093/esj/aakag001.
- Derived from this study: PubMed 40982270Engelter ST, Kaufmann JE, Zietz A, Luft AR, Polymeris A, Altersberger VL, Wiesner K, Wiegert M, Held JPO, Rottenberger Y, Schwarz A, Medlin F, Accolla EA, Foucras S, Kagi G, De Marchis GM, Politz S, Greulich M, Tarnutzer AA, Sturzenegger R, Katan M, Fischer U, Nedeltchev K, Schar J, Van Den Keybus Deglon K, Rapin PA, Salerno A, Seiffge DJ, Auer E, Lippert J, Bonati LH, Schuster-Amft C, Gaumann S, Chabwine JN, Humm A, Moller JC, Schweinfurther R, Bujan B, Jedrysiak P, Sandor PS, Gonzenbach R, Mylius V, Lutz D, Lienert C, Peters N, Michel P, Muri RM, Schadelin S, Hemkens LG, Ford GA, Lyrer PA, Gensicke H, Traenka C; ESTREL Investigators. Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial. JAMA. 2025 Nov 4;334(17):1523-1532. doi: 10.1001/jama.2025.15185.
Related trials for Acute Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
RecruitingObservational study
Continuous Dual Aspiration Technique With Zoom System for Stroke
Ischemic Stroke, Acute Stroke
Not yet recruitingPhase 2/3
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stefan Engelter, Prof. MD principal investigator
Felix-Platter Spital Basel
24 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing IMP Levodopa 100mg/Carbidopa 25mg in people with Acute Stroke and Stroke Rehabilitation, run by University Hospital, Basel, Switzerland at 24 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 15 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 24 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fugl-Meyer-Motor Assessment Score (FMMA) (time frame: Assessed 3 months +/- 14 days after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03735901, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2024.